IOVANCE BIOTHERAPEUTICS, INC. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $30.63 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-08-06
- 2026-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $30.63M.
- 2026-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $31.50M.
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $32.39M.
- 2025-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $33.36M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2026-06-30 | $30.63M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $31.50M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $32.39M 10-K · filed 2026-02-24 |
| 2025-09-30 | $33.36M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $34.21M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $34.89M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $35.82M 10-K · filed 2025-02-27 |
| 2024-09-30 | $45.51M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $44.95M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $46.55M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $46.39M 10-K · filed 2024-02-28 |
| 2023-09-30 | $47.85M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $49.16M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $50.69M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $52.21M 10-K · filed 2023-02-28 |
| 2022-09-30 | $52.98M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $54.39M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $55.73M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $56.60M 10-K · filed 2022-02-24 |
| 2021-09-30 | $66.09M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $47.13M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $48.09M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $51.75M 10-K · filed 2021-02-25 |
| 2020-09-30 | $607.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |